Poster 045: Esca-Too-Late? Timing of Escalation to Impella 5.5 in Refractory Cardiogenic Shock: A Single-Center Case Series

Background: Temporary mechanical circulatory support improves hemodynamics in cardiogenic shock, but optimal timing for escalation to high-flow devices like Impella 5.5 remains unclear. We examined whether physiologic severity at the time of Impella 5.5 implantation reflects late escalation and is associated with poor outcomes compared to upfront high-flow support.

Methods: We conducted a single-center, retrospective case series of patients who received Impella 5.5 support between December 2022 and July 2025 at a non-tertiary hospital serving a predominantly rural population. De-identified clinical data were obtained from the Abiomed sales registry. Because the dataset contained no protected health information, institutional review board approval was not required.
Baseline demographics and clinical characteristics were collected, including shock severity at the time of implantation. Patients were stratified based on whether Impella 5.5 was placed as initial mechanical circulatory support or as an escalation from lower-flow devices (e.g., Impella CP). Physiologic severity (SCAI stage, vasoactive support) and clinical outcomes were analyzed descriptively, with survival to device explant as the primary endpoint.

Outcome: A total of 28 patients were included. The majority were male (89%), with a median age of 66 years. Indications for support included acute myocardial infarction with cardiogenic shock (46%), post-cardiotomy shock (29%), pre-operative placement (14%), cardiomyopathy (7%), and high-risk PCI (4%). At the time of Impella 5.5 placement, 82% of patients were in SCAI stage D or E, and 57% required three or more vasoactive agents, indicating advanced shock at baseline. Overall survival to device explant was 43%, substantially lower than rates reported in national shock registries.
Impella 5.5 was used as initial support in 39% (11/28) of patients and as an escalation strategy in 61% (17/28). The initial support group exhibited more severe hemodynamic shock at baseline, with higher rates of SCAI stage D/E (100% vs 71%) and greater vasoactive requirements (82% vs 41% on ≥3 pressors). The escalation group more frequently demonstrated catastrophic clinical deterioration, including higher rates of cardiac arrest following implantation (53% vs 18%). Despite greater baseline hemodynamic severity, survival was higher in the initial support group (55%) compared with the escalation group (35%).

Conclusion: Upfront Impella 5.5 support was associated with higher survival than escalation from lower-flow devices, despite greater initial hemodynamic severity. These findings suggest that delayed escalation may permit irreversible clinical collapse. Defining physiologic thresholds for earlier transition to high-flow support may be critical to improving outcomes in refractory cardiogenic shock.